Shares of KemPharm Inc. (NASDAQ:KMPH) rose 5.9% on Thursday . The company traded as high as $4.58 and last traded at $4.48, with a volume of 58,153 shares. The stock had previously closed at $4.23.

KMPH has been the subject of a number of analyst reports. Canaccord Genuity reaffirmed a “buy” rating on shares of KemPharm in a research report on Tuesday, May 3rd. Zacks Investment Research cut KemPharm from a “hold” rating to a “sell” rating in a research report on Wednesday, May 4th. Royal Bank Of Canada reduced their price target on KemPharm from $22.00 to $14.00 and set an “outperform” rating for the company in a research report on Friday, May 6th. Finally, Oppenheimer Holdings Inc. reissued a “buy” rating on shares of KemPharm in a research report on Saturday, May 14th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. KemPharm currently has an average rating of “Buy” and a consensus target price of $26.80.

The firm’s market capitalization is $65.89 million. The firm has a 50-day moving average of $4.93 and a 200-day moving average of $11.89.

KemPharm (NASDAQ:KMPH) last released its earnings results on Thursday, May 12th. The specialty pharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.46) by $0.26. Equities analysts forecast that KemPharm Inc. will post ($2.79) earnings per share for the current fiscal year.

An institutional investor recently raised its position in KemPharm stock. EAM Investors LLC increased its stake in shares of KemPharm Inc. (NASDAQ:KMPH) by 0.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 61,253 shares of the specialty pharmaceutical company’s stock after buying an additional 240 shares during the period. EAM Investors LLC owned 0.42% of KemPharm worth $1,216,000 as of its most recent filing with the SEC.

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. It uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs by chemically attaching one or more molecules, referred to as ligands, to the parent drug.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.